MARKET

BNR

BNR

Burning Rock Biotech Ltd
NASDAQ
3.210
+0.040
+1.26%
Closed 16:00 01/27 EST
OPEN
3.230
PREV CLOSE
3.170
HIGH
3.270
LOW
3.080
VOLUME
160.69K
TURNOVER
312.68K
52 WEEK HIGH
11.27
52 WEEK LOW
1.700
MARKET CAP
337.65M
P/E (TTM)
-2.3718
1D
5D
1M
3M
1Y
5Y
reported Late Tuesday, Burning Rock Provides An Update On 2022 Revenue Guidance; Sees FY22 Revenue Growth To Be ~10% YoY
Benzinga · 01/18 05:32
Burning Rock Biotech Lifts 2022 Revenue Growth Guidance
Burning Rock Biotech Lifts 2022 Revenue Growth Guidance
MT Newswires · 01/18 03:42
BRIEF-Burning Rock Provides An Update On 2022 Revenue Guidance
Reuters · 01/18 01:38
Burning Rock spikes on FDA breakthrough device designation for cancer test
Seeking Alpha · 01/03 14:59
BRIEF-Burning Rock Receives FDA Breakthrough Device Designation For OverC Multi-Cancer Detection Blood Test
Reuters · 01/03 14:27
Here’s how the Silbert-Winklevoss feud may play out, says top crypto watcher
MarketWatch · 01/03 11:51
Burning Rock Biotech Gets US FDA's Breakthrough Device Designation for Multi-Cancer Detection Blood Test
Burning Rock Biotech Gets US FDA's Breakthrough Device Designation for Multi-Cancer Detection Blood Test
MT Newswires · 01/03 10:07
Burning Rock Biotech Limited Sponsored ADR (BNR) Upgraded to Buy: What Does It Mean for the Stock?
Burning Rock Biotech Limited Sponsored ADR (BNR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks · 11/21/2022 17:00
More
About BNR
Burning Rock Biotech Ltd is a holding company mainly engaged in the next generation sequencing (NGS) based cancer therapy selection. The Company operates three segments. Central Laboratory Business segment is engaged in the sales of cancer therapy selection test to individual patients. In-Hospital Business segment is engaged in the sales of reagent kits and the provision of the facilitation services for the sale of laboratory equipment to hospitals. Pharma Research and Development Services segment provide services to companies primarily in relation to the development of targeted therapies and immunotherapies for various types of cancer, and to hospitals for their studies on cancer diagnosis and treatment. Its products include OncoScreen Plus and LungPlasma. Its NGS-based cancer therapy selection tests applicable to a broad range of cancer types, including lung cancer, prostate cancer, breast cancer and others. The Company mainly conducts its businesses in the China market.

Webull offers kinds of Burning Rock Biotech Ltd(ADR) stock information, including NASDAQ:BNR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BNR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BNR stock methods without spending real money on the virtual paper trading platform.